NR1H4 and obesity disorder: The FXR agonists 6-ethyl-chenodeoxycholic acid, fexaramine, and GW 4064 and FXR overexpression improve the metabolic profile in a mouse obesity model (Zhang et al. 2006, Cipriani et al. 2010, Fang et al. 2015).